It Way Stock Quote ITW - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1.336

Bid

0.00

Ask

1.344

Volume

0.00

0.00 Day's Range 0.00

1.244 52 Week Range 2.37

Market Cap

14.091M

Previous Close

1.336

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

16,133

Shares Outstanding

10,547,224

Dividend Yield

PE Ratio

-45.21

Earnings Per Share (EPS)

-0.03

Revenue

49.09M

Net Profit

-275k

Sector

Computers & Software-whsl

Industry

Computers & Software-whsl

Website

www.itway.com

Headquarters

Ravenna, Ravenna, Ita

Founded

1970

It Way SPA is listed in the Computers & Software-whsl sector of the Italian Stock Exchange with ticker ITW. The last closing price for It Way was 1.34 €. Over the last year, It Way shares have traded in a share price range of 1.244 € to 2.37 €.

It Way currently has 10,547,224 shares outstanding. The market capitalization of It Way is 14.09 € million. It Way has a price to earnings ratio (PE ratio) of -45.21.

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate Valneva obtains exclusive...

Valneva et LimmaTech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au monde

Valneva et LimmaTech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au monde Valneva obtient une licence...

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront...

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine Valneva to receive up to $41.3 million from CEPI and the...

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ®Funding will support clinical trials in vulnerable groups, such as children...

CEPI renforce son partenariat avec Valneva en lui octroyant un nouveau financement de $41,3 millions visant à accroître l’accessibilité du premier vaccin au monde contre le chikungunya

CEPI renforce son partenariat avec Valneva en lui octroyant un nouveau financement de $41,3 millions visant à accroître l’accessibilité du premier vaccin au monde contre le chikungunya Valneva...

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion Participants completed primary vaccination series (3 doses) with VLA15Primary vaccination...

Essai de Phase 3 VALOR sur la maladie de Lyme : Valneva et Pfizer finalisent la vaccination primaire de tous les participants

Essai de Phase 3 VALOR sur la maladie de Lyme : Valneva et Pfizer finalisent la vaccination primaire de tous les participants Les participants à l’essai ont reçu les trois doses de VLA15 de la...

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Participants completed primary vaccination series (3 doses) with VLA15Primary vaccination series to be followed by a booster approximately one year after completion New York, NY and...

Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024

Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024 VALNEVA Déclaration d’actions et de droits de vote 30 juin 2024__________________________________________________________...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.008	-0.595238095238	1.344	1.346	1.308	6201	1.33567474	DE
4	-0.04	-2.90697674419	1.376	1.438	1.308	13334	1.36086376	DE
12	-0.04	-2.90697674419	1.376	1.528	1.308	16133	1.39506822	DE
26	-0.224	-14.358974359	1.56	1.72	1.244	23874	1.46084759	DE
52	-0.356	-21.0401891253	1.692	2.37	1.244	55241	1.86182141	DE
156	0.286	27.2380952381	1.05	3.32	1.035	89215	2.01780884	DE
260	0.62	86.5921787709	0.716	3.32	0.289	83568	1.65958473	DE

Symbol	Price	Vol.
1AAAlcoa Corp	29.86 € (0.00%)	0
1AAgilent Technologies Inc	125.32 € (0.00%)	0
19MWMarvell Technology Inc	61.32 € (0.00%)	0
18TRATraton SE	31.50 € (0.00%)	0
11COVCovestro AG	54.64 € (0.00%)	0
1AAAlcoa Corp	29.86 € (0.00%)	0
1AAgilent Technologies Inc	125.32 € (0.00%)	0
19MWMarvell Technology Inc	61.32 € (0.00%)	0
18TRATraton SE	31.50 € (0.00%)	0
11COVCovestro AG	54.64 € (0.00%)	0
1AAAlcoa Corp	29.86 € (0.00%)	0
1AAgilent Technologies Inc	125.32 € (0.00%)	0
19MWMarvell Technology Inc	61.32 € (0.00%)	0
18TRATraton SE	31.50 € (0.00%)	0
11COVCovestro AG	54.64 € (0.00%)	0

Symbol

Price

Vol.

1AAAlcoa Corp

29.86 €

(0.00%)

1AAgilent Technologies Inc

125.32 €

(0.00%)

19MWMarvell Technology Inc

61.32 €

(0.00%)

18TRATraton SE

31.50 €

(0.00%)

11COVCovestro AG

54.64 €

(0.00%)

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

It Way SPA (ITW)

Professional-Grade Tools, for Individual Investors.

Key stats and details

About It Way SPA

ITW Latest News

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

Valneva et LimmaTech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au monde

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

CEPI renforce son partenariat avec Valneva en lui octroyant un nouveau financement de $41,3 millions visant à accroître l’accessibilité du premier vaccin au monde contre le chikungunya

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Essai de Phase 3 VALOR sur la maladie de Lyme : Valneva et Pfizer finalisent la vaccination primaire de tous les participants

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

It Way SPA (ITW) Quote

It Way SPA (ITW)

Professional-Grade Tools, for Individual Investors.

Key stats and details

About It Way SPA

ITW Latest News

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App